Understanding and Managing Risk in HCP Interactions
Interactions between life sciences companies and healthcare professionals (HCPs) are essential to the development, appropriate use, and ongoing improvement of medicines.
When done well, these interactions support scientific exchange, education, and better patient outcomes. When poorly designed or managed, they can create significant compliance, reputational and operational risk.
For organisations transitioning from R&D into late‑stage development or commercialisation in particular, HCP interactions often expand rapidly, probably before governance frameworks are mature enough to support them. The result is often inconsistency, misalignment, or failure to document engagements effectively.
This article explores the some of the risks associated with HCP interactions, why they arise, and practical ways to manage them, drawing on personal experience across global regulatory environments.
1. The Risk of Blurred Scientific and Promotional Intent
Why it matters
One of the most common risks in HCP engagement is the blurring of boundaries between legitimate scientific exchange and promotional activity. This is particularly acute:
- pre‑launch,
- where Medical and Commercial roles interact closely, or
- when products are approved in one geography but not another.
Most regulatory and industry codes emphasise that promotion must be clearly separated from scientific exchange, particularly for prescription‑only medicines.
How this risk materialises
- Data is presented without appropriate context or balance
- HCP discussions drift into off‑label territory
- Commercial objectives influence scientific material structure or messaging
- MSL or Medical roles are asked to “support” commercial narratives
Pragmatic ways to address
- Clearly document the purpose of each HCP interaction (scientific, advisory, educational, promotional)
- Separate scientific narrative presentations from commercial core materials
- Train Medical and Commercial teams together on where the boundary sits in practice with practical examples and facilitated discussions
2. Inappropriate Value Transfer and Perceived Inducement
Why it matters
Even modest meals, travel or consultancy fees can attract scrutiny if they appear disproportionate, they are not adequately justified, or they are linked to potential prescribers. Codes are explicit that transfers of value must never be an inducement to prescribe, recommend or use a medicine.
Global requirements vary significantly in the detail:
- In the UK and much of Europe, proportionality and intent are heavily scrutinised (ABPI, EFPIA).
- In the US, public disclosure via the Sunshine Act means even compliant transfers can carry reputational risk if poorly explained.
How this risk materialises
- Inconsistent application of fair market value (FMV)
- Practices transferred from other regions without checking local requirements
- Hospitality that may be technically compliant but might be perceived negatively
- Repeat engagement of the same HCPs without a documented (and justified) rationale
Pragmatic ways to address
- Apply FMV frameworks consistently, and document assumptions
- Implement a robust HCP selection process and rationale
- Design engagement strategies that spreads engagements across multiple qualified HCPs, rather than relying on the same “trusted voices”
- Consider reputational impact from the start, not just the technical compliance of the engagement
3. Transparency and Disclosure Failures
Why it matters
Transparency has become one of the most complex aspects of HCP engagement. While global principles are aligned, implementation varies widely:
- EFPIA requires disclosure of transfers of value across Europe, subject to data privacy rules
- The US Open Payments regime mandates public reporting and this downstream scrutiny by media and regulators
- Countries such as France (in particular), Japan and Australia apply additional local requirements
How this risk materialises
- Data captured inconsistently across systems
- Cross‑border activities allocated incorrectly
- HCP consent (where required) obtained too late or not at all
- Disconnect between engagement design and what is provided to the transparency reporting team
Pragmatic ways to address
- Design transparency into the interaction model, not as a post‑event activity
- Map and document every HCP touchpoint that creates a Transfer of Value
- Align Medical, Finance and Compliance early on how data will be captured and from what systems
- Recognise that transparency is not just a reporting exercise. It requires effective governance and approvals
4. Inconsistent Global Application of Standards
Why it matters
Many organisations operate across borders before they operate at scale. This often leads to inconsistent application of standards, particularly when local requirements conflict with global expectations.
While codes such as IFPMA, EFPIA and PhRMA align on principles, interpretation and enforcement may differ by market.
How this risk materialises
- “Local custom” used to justify weaker controls
- Global policies that are technically compliant but operationally unusable
- Confusion among field teams working across multiple regions
Pragmatic ways to address
- Define non‑negotiable global guardrails, with flexible local implementation
- Focus on principles‑based training, not country checklists
- Encourage teams to escalate uncertainty early rather than explain any workarounds later
Closing Thoughts
Effective risk mitigation in this area does not mean eliminating interactions with HCPs or defaulting to multiple approvals. It means recognising where risk genuinely sits and addressing it before it becomes embedded in ways of working. This requires:
- Clarity of purpose for every HCP engagement,
- Proportionate controls that support rather than replace professional judgement, and
- Governance that keeps pace with how engagement models evolve, particularly as organisations scale or expand internationally.
As expectations around transparency, accountability and ethical conduct continue to rise globally, HCP interactions will remain an area of sustained regulatory and public focus. Organisations that take these risks seriously, by designing mitigations that are practical, defensible and consistently applied, are far better positioned to operate with confidence, withstand scrutiny and maintain trust with healthcare professionals, patients and regulators alike.
How GRC Catalyst helps
Disclosure
The concepts and ideas in this article are mine or have been referenced; I developed the body of the text and conducted the final editorial check. I used AI as a tool for research, to improve the flow and grammar of the article, and to check for factual inaccuracies.
